MDxHealth SA (O6C1)

Overview

MDxHealth SA is a commercial-stage precision diagnostics company that specializes in innovative urologic solutions. With a firm presence in the United States, Europe, and various international markets, the company leverages cutting-edge technology to advance the diagnosis of urological conditions, primarily focusing on prostate cancer. MDxHealth’s journey began as OncoMethylome Sciences SA, after which it underwent a rebranding to its current name in October 2010, signaling a focused strategic direction. Since its incorporation in 2003, headquartered in Herstal, Belgium, MDxHealth has dedicated itself to the development and commercialization of genomic testing solutions designed to improve patient outcomes while minimizing unnecessary medical procedures.

Products and Services

• SelectMDx

  This non-invasive urine test represents a significant leap in the early detection of prostate cancer. SelectMDx leverages molecular diagnostics to analyze genetic markers, offering clinicians a powerful tool to assess the risk of prostate cancer without the need for invasive testing procedures. By identifying patients at higher risk, SelectMDx facilitates a tailored clinical approach, ensuring that invasive interventions, such as biopsies, are reserved for those most likely to benefit from them.

• ConfirmMDx

  An epigenetic test that addresses the limitations of traditional biopsy procedures. ConfirmMDx is designed to detect the epigenetic changes associated with prostate cancer, offering a level of diagnostic insight beyond what typical histological analysis can provide. This test helps in reducing the risk of false-negative biopsy results, thereby helping clinicians to make more informed decisions regarding the necessity for repeat biopsies. By providing a molecular understanding of the prostate tissue, ConfirmMDx plays a crucial role in distinguishing between patients who have a higher likelihood of harboring clinically significant prostate cancer and those who do not.